KRAS and cancer: To account for possible interactome changes due to cell type-specific protein expression, a BioID screen of the interactomes of the wildtype HRAS, KRAS4B and NRAS proteins and the most commons mutations of these proteins, HRASG12V, KRASG12D and NRASQ61 was carried out in cancer cell lines where these mutations usually occur (HRAS, bladder; KRAS, colorectal cancer; NRAS, melanoma) [134].